Xtandi 40 MG capsule 120S
Ended Awarded
- Contract number
- SPE2DB25FSYYE
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $8,623
Award facts
- Contract value 100% obligated
- $8,622.72 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units) with a ceiling value of $8,622.72. This delivery order, issued on August 22, 2025, with an ultimate completion date of August 25, 2025, operates under a firm fixed-price structure with no set-aside designation. The award falls under DMS Pharmaceutical Group's existing single-award Indefinite Delivery Contract with the DLA valued at $499.999 billion and valid through November 2026, which authorizes the agency to issue delivery orders for pharmaceutical products supporting the medical supply needs of military healthcare facilities worldwide.
Xtandi, a prescription medication used in oncology treatments, represents part of the comprehensive pharmaceutical portfolio that DMS Pharmaceutical Group supplies to federal agencies through its core business of distributing branded and generic prescription drugs, biologics, and medical consumables. The company's contract awards demonstrate consistent success in competing for federal pharmaceutical procurement without set-aside designations, leveraging its woman-owned small business status to secure multiple delivery orders across diverse product categories. This particular delivery order exemplifies the company's established role as a critical supplier within the federal pharmaceutical supply chain, providing direct distribution of specialty medications to Department of Defense healthcare sites.
Quick answers
Who was awarded contract SPE2DB25FSYYE?
SPE2DB25FSYYE was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on August 22, 2025.
How much is contract SPE2DB25FSYYE worth?
The government has obligated $8,623 on SPE2DB25FSYYE.
Is contract SPE2DB25FSYYE an order under another contract?
Yes. SPE2DB25FSYYE is a delivery order under SPE2DB25D9349, an indefinite delivery contract.
Was contract SPE2DB25FSYYE competed?
The extent of competition for SPE2DB25FSYYE was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award